Consumer brands-focused venture capital firm Prelude Growth Partners initiates a strategic partnership with OneSkin, a cutting-edge skin longevity startup in the wellness space.
OneSkin, a skin longevity company founded by female PhD scientists, has secured a $20 million Series A investment from Prelude Growth Partners, a major milestone in skin longevity innovation.
The company’s leadership team has expertise in stem cell biology, bioinformatics, and tissue engineering. Their combined backgrounds bridge biotech research and consumer product development, bringing technical knowledge and entrepreneurial drive to wellness.
A Strategic Match: From Seed Investor to Growth Partner
OneSkin was not actively seeking new capital when Prelude Growth Partners approached the company with an investment offer. OneSkin’s embrace of this partnership relationship moves it from an early seed-stage startup to a growth-stage company.
“This was not about raising money for the sake of capital,” said Carolina Reis Oliveira, PhD, Co-Founder and CEO of OneSkin. “Prelude’s expertise in scaling modern consumer brands, paired with their belief in our science-driven vision, made them an ideal partner. We weren’t looking, but when the right team came to us, we knew it was the right moment to take OneSkin to the next level.”
Prelude Growth Partners, based in New York, has a reputation for investing in high-potential, founder-led consumer brands across the beauty, personal care, food, beverage, and wellness sectors.
The firm’s track record includes backing several female-founded businesses that have since become category leaders.
Science at the Core: Targeting Skinspan, Not Just Skincare
OneSkin stands out for its focus on “skin longevity”, extending skinspan which is the period skin remains healthy and functional. Instead of targeting aesthetics, the brand bases its work on biotech and longevity science.
The company’s research centers on senescent cells, the aged cells that accumulate in tissue and contribute to chronic inflammation, collagen breakdown, and visible aging.
OneSkin’s proprietary peptide, OS-01, is designed to reduce the burden of these cells, thereby restoring skin function and making it look, feel, and behave more like younger skin.
By addressing aging at its biological root, OneSkin sits at the intersection of healthspan research and consumer beauty. This is appealing to those seeking benefits beyond appearance.
A Growing Product Portfolio
OneSkin’s offerings have expanded rapidly in recent years, with products such as OS-01 FACE, BODY, and EYE gaining a loyal customer base. More recently, the company introduced OS-01 LIP and OS-01 HAIR, extending its science-first approach to new areas of personal care.
Clinical data support these products and have received endorsements from both consumers and public figures.
All products are available through OneSkin’s direct-to-consumer platform, www.oneskin.co, allowing the company to maintain a close relationship with its community while building a data-driven understanding of consumer needs.
Industry Validation Gains Investor Confidence
The Series A funding from Prelude Growth Partners comes after backing from Selva Ventures, Unilever Ventures, Plus Capital, SOSV, Meta Planet, Able Partners, and 2Future. Such notable support shows increasing institutional recognition of longevity science in the health and wellness industry.
“OneSkin’s cutting-edge science, proprietary technology, and leadership in the emerging skin longevity space make it uniquely positioned to define a new category,” said Alicia Sontag, Co-Founder and Managing Partner of Prelude Growth. “We’re proud to support Carolina, Alessandra, and the team as they build an iconic brand of the future.”
What’s Next for OneSkin
The investment is expected to accelerate product development, enhance consumer education on longevity science, and facilitate new partnerships in biotech and wellness.
Notably, the investment also signals a maturing of the longevity category. As consumers become increasingly conscious of aging and health span, brands that can demonstrate scientific rigor and tangible outcomes are likely to lead the market.
By combining biotech innovation with consumer accessibility, OneSkin seeks to shape the future of skin longevity.
